Cost-effectiveness of replacing NSAIDs with coxibs: diclofenac and celecoxib in rheumatoid arthritis.
Cyclooxygenase-2 inhibitors exhibit the same effectiveness on rheumatic symptoms as nonsteroidal anti-inflammatory drugs, have fewer gastrointestinal side effects, but a higher price. Based on cost and healthcare utilization in Norway, this paper explores what factors are most important for the cost-effectiveness of cyclooxygenase-2 inhibitors and points to patient groups that may be most relevant for prescribing coxibs instead of nonsteroidal anti-inflammatory drugs.
Kristiansen
Ivar Sønbø
IS
Institute of Public Health - Health Economics Research Unit, University of Southern Denmark, Odense, 19 Winsløw Park, DK-5000 Odense C, Denmark. isk@sam.sdu.dk
Kvien
Tore Kristian
TK